全文获取类型
收费全文 | 440178篇 |
免费 | 28490篇 |
国内免费 | 2914篇 |
专业分类
耳鼻咽喉 | 6175篇 |
儿科学 | 10608篇 |
妇产科学 | 12005篇 |
基础医学 | 61252篇 |
口腔科学 | 14588篇 |
临床医学 | 35607篇 |
内科学 | 89286篇 |
皮肤病学 | 9624篇 |
神经病学 | 32767篇 |
特种医学 | 16102篇 |
外国民族医学 | 83篇 |
外科学 | 69744篇 |
综合类 | 10229篇 |
现状与发展 | 1篇 |
一般理论 | 75篇 |
预防医学 | 22834篇 |
眼科学 | 10668篇 |
药学 | 35188篇 |
1篇 | |
中国医学 | 2327篇 |
肿瘤学 | 32418篇 |
出版年
2021年 | 3565篇 |
2019年 | 3757篇 |
2018年 | 6012篇 |
2017年 | 4662篇 |
2016年 | 4927篇 |
2015年 | 5413篇 |
2014年 | 7389篇 |
2013年 | 10005篇 |
2012年 | 13227篇 |
2011年 | 13565篇 |
2010年 | 8173篇 |
2009年 | 7520篇 |
2008年 | 11979篇 |
2007年 | 13128篇 |
2006年 | 12850篇 |
2005年 | 11982篇 |
2004年 | 11248篇 |
2003年 | 10860篇 |
2002年 | 10360篇 |
2001年 | 29938篇 |
2000年 | 30447篇 |
1999年 | 25162篇 |
1998年 | 5740篇 |
1997年 | 4736篇 |
1996年 | 4269篇 |
1995年 | 3890篇 |
1994年 | 3480篇 |
1993年 | 3164篇 |
1992年 | 17143篇 |
1991年 | 15829篇 |
1990年 | 15231篇 |
1989年 | 15005篇 |
1988年 | 13557篇 |
1987年 | 13006篇 |
1986年 | 12003篇 |
1985年 | 11184篇 |
1984年 | 7647篇 |
1983年 | 6177篇 |
1982年 | 3080篇 |
1979年 | 6074篇 |
1978年 | 3769篇 |
1977年 | 3318篇 |
1975年 | 3032篇 |
1974年 | 3511篇 |
1973年 | 3291篇 |
1972年 | 3241篇 |
1971年 | 3146篇 |
1970年 | 2850篇 |
1969年 | 2885篇 |
1968年 | 2585篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
21.
22.
23.
L.‐Q. Zheng X.‐C. Han Y. Huang H.‐W. Li X.‐D. Niu J. Li 《Clinical and experimental dermatology》2015,40(3):293-297
Porocarcinoma is an unusual, locally aggressive and potentially fatal neoplasm. Several cutaneous malignancies have been described in association with porocarcinoma, including squamous cell carcinoma, basal cell carcinoma and tricholemmal carcinoma. Previous reports have indicated that the occurrence of malignant tumours in combination with porocarcinoma is extremely rare, in particular with regard to Bowen disease (BD). We report an uncommon case of porocarcinoma occurring synchronously in a single BD lesion in a 63‐year‐old woman with multiple BD lesions. The clinical and histological findings confirmed this diagnosis. 相似文献
24.
In the 6th Basic Plan for Long-Term Electricity Supply and Demand (6th BPE) for Korea, for the first time, the environmental costs of air pollution caused by oxides of sulfur (SOx), oxides of nitrogen (NOx), and particulate matters (PM) from power plants were estimated and included. However, several deficiencies in evaluating the environmental costs were found. In this study, (1) the validity of the environmental costs used in the 6th BPE was assessed, (2) a systematic approach was suggested and used to improve the environmental costs estimation, and (3) the sensitivity of the cost of generating electricity to the environmental costs by fuel type with the proposed approach was discussed. We found that the applied environmental costs used in the 6th BPE did not fully include the demographic characteristics of Korea. By applying more realistic parameter values, it was found that the newly estimated environmental cost was about 23 times higher than the cost estimated in the original 6th BPE for coal-fired power plants and about 1.5 times higher for liquefied natural gas (LNG)-fired power plants, suggesting that LNG-fired power plants are more economical if using more realistic environmental costs. Thus, it is critical to check the validity of parameter values when calculating environmental costs. 相似文献
25.
Evaluation of Adult versus Pediatric Transesophageal Echocardiography Probe Efficiency for Guiding Septal Puncture during Atrial Fibrillation Ablation 下载免费PDF全文
26.
27.
Edward J. Holland Walter O. Whitley Kenneth Sall Stephen S. Lane Aparna Raychaudhuri Steven Y. Zhang 《Current medical research and opinion》2016,32(10):1759-1765
Objective: Report efficacy findings from three clinical trials (one phase 2 and two phase 3 [OPUS-1, OPUS-2]) of lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease (DED).Research design and methods: Three 84-day, randomized, double-masked, placebo-controlled trials. Adults (≥18 years) with DED were randomized (1:1) to lifitegrast 5.0% or matching placebo. Changes from baseline to day 84 in signs and symptoms of DED were analyzed.Main outcome measures: Phase 2, pre-specified endpoint: inferior corneal staining score (ICSS; 0–4); OPUS-1, coprimary endpoints: ICSS and visual-related function subscale (0–4 scale); OPUS-2, coprimary endpoints: ICSS and eye dryness score (EDS, VAS; 0–100).Results: Fifty-eight participants were randomized to lifitegrast 5.0% and 58 to placebo in the phase 2 trial; 293 to lifitegrast and 295 to placebo in OPUS-1; 358 to lifitegrast and 360 to placebo in OPUS-2. In participants with mild-to-moderate baseline DED symptomatology, lifitegrast improved ICSS versus placebo in the phase 2 study (treatment effect, 0.35; 95% CI, 0.05–0.65; p?=?0.0209) and OPUS-1 (effect, 0.24; 95% CI, 0.10–0.38; p?=?0.0007). Among more symptomatic participants (baseline EDS ≥40, recent artificial tear use), lifitegrast improved EDS versus placebo in a post hoc analysis of OPUS-1 (effect, 13.34; 95% CI, 2.35–24.33; nominal p?=?0.0178) and in OPUS-2 (effect, 12.61; 95% CI, 8.51–16.70; p?<?0.0001).Limitations: Trials were conducted over 12 weeks; efficacy beyond this period was not assessed.Conclusions: Across three trials, lifitegrast improved ICSS in participants with mild-to-moderate baseline symptomatology in two studies, and EDS in participants with moderate-to-severe baseline symptomatology in two studies. Based on the overall findings from these trials, lifitegrast shows promise as a new treatment option for signs and symptoms of DED. 相似文献
28.
Rafiye Ciftciler Haluk Demiroglu Yahya Buyukasık Elifcan Aladag Salih Aksu Ibrahim C. Haznedaroglu Nilgun Sayınalp Osman Ozcebe Umit Yavuz Malkan Hakan Goker 《Clinical Lymphoma, Myeloma & Leukemia》2019,19(3):177-182
Background
Refractory acute myeloid leukemia (AML) includes AML includes failure of disease to respond to standard induction chemotherapy, relapse within 6 months after first CR, and 2 or more relapses. The outcome of these patients is usually very poor; only a small proportion can be rescued by allogenic hematopoietic stem-cell transplantation (allo-HSCT). The aim of this study was to evaluate the efficacy and feasibility of allo-HSCT in patients with refractory AML.Patients and Methods
We retrospectively analyzed the clinical outcome of 91 patients who were diagnosed with treatment-refractory AML at Hacettepe University Hospital between January 2002 and June 2018. Patients' disease status included refractory AML, defined as failure to respond to standard induction chemotherapy and relapse within 6 months after first complete remission.Results
The median follow-up was 12 months (range, 0.5-184 months) for the entire group. Kaplan-Meier estimates of the 3-year overall survival for patients who underwent allo-HSCT and patients who received only salvage chemotherapy were 67% and 12%, respectively. Additionally, the Kaplan-Meier estimates of 5-year overall survival for patients who underwent allo-HSCT and patients who received only salvage chemotherapy were 44% and 4%, respectively (P < .001). Complete remission was obtained in 25 patients (83.3%) who underwent allo-HSCT; however, the disease of only 3 patients (3.8%) exhibited complete response after salvage chemotherapy.Conclusion
Allo-HSCT is still the best-known treatment option with curative potential in patients with treatment-refractory AML. Therefore, all efforts should be made in an attempt to find a suitable matched donor in order to perform allo-HSCT. 相似文献29.
A case of bullous pemphigoid associated with psoriasis vulgaris showing Hailey–Hailey disease‐like histopathological changes in regenerated epidermis without genomic mutation in ATP2C1 or ATP2A2 gene 下载免费PDF全文
30.